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Change in the treatment strategy for pediatric Crohn’s 
disease
Crohn’s disease is characterized by chronic inflammation involving 
any portion of the gastrointestinal tract. Treating Crohn’s disease is a 
major challenge for clinicians, as no curative therapy currently exists. 
Pediatric Crohn’s disease is characterized by frequent relapses, a wide 
extent of disease, a high prevalence of extraintestinal manifestations, 
and a severe clinical course. The classic therapeutic approach is 
known as the ‘step-up’ strategy, and follows a progressive course of 
treatment intensification as disease severity increases. Although this 
approach is usually effective for symptom control, many patients 
become either resistant to or dependent on corticosteroids. The 
efficacy of infliximab suggests that, rather than a progressive course 
of treatment, early intense induction may reduce complications 
associated with conventional treatment and improve quality of life. 
Intensive early therapy with infliximab is known as the ‘top-down’ 
strategy. Such therapy offers the potential for altering the natural history 
of Crohn’s disease, and is changing treatment paradigms. However, the 
relatively new concept of an early aggressive or ‘top-down’ treatment 
approach is not yet widely accepted, especially in pediatric patients. 
The results of our current study demonstrate that early and intensive 
treatment of pediatric Crohn’s disease patients with infliximab, at initial 
diagnosis, was more effective for maintaining remission and reducing 
flares.   
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Introducation
Crohn’s disease (CD) is characterized by chronic inflammation 
involving any portion of the gastrointestinal tract. Although the 
etiology of CD remains incompletely understood, environmental 
factors, infectious microbes, ethnic origin, genetic susceptibility, 
and immune system dysfunction have been implicated in the 
associated chronic mucosal inflammation
1). Treating CD is a major 
challenge for clinicians, as no curative therapy currently exists. The 
classic therapeutic approach is known as the “step-up” strategy, and 
follows a progressive course of treatment intensification as disease 
severity increases (Fig. 1).
Conventional therapy for active disease includes treatment 
with corticosteroids. Initially, corticosteroids are very effective 
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and fast acting; however, long-term exposure to corticosteroids 
leads to drug dependency and/or resistance
2).Several randomized, 
placebo-controlled studies have demonstrated that the biological 
drug infliximab (Remicade: Centocor Ortho Biotech, Malvern, 
PA, USA), a monoclonal immunoglobulin G1 chimeric antibody 
directed against tumor necrosis factor-α , is highly effective in 
improving the clinical course in patients with CD
3-9). Since 
receiving FDA approval for pediatric use in May 2006, infliximab 
has been widely used in pediatric patients with CD
10). The efficacy 
of infliximab suggests that, rather than a progressive course of 
treatment, early intense induction may reduce complications 
associated with conventional treatment and improve quality of life. 
Intensive early therapy with infliximab is known as the “top-down” 
strategy (Fig. 1). 
Ethnic differences in the clinical characteristics of CD have been 
noted. CD is relatively common in developed countries, whereas 
it is not as common in Asian countries
11). In addition, recent 
studies from Far East Asian countries reveal that the prevalence 
of NOD2 mutations, associated with increased susceptibility to 
CD in Western populations, is lower than that found in other 
populations
12-14). Therefore, the clinical response to treatment 
for CD in Asian countries might differ from patients in Western 
countries.
Step-up strategy 
Pediatric CD is characterized by frequent relapses, wide disease 
extent, high prevalence of extraintestinal manifestations, and   
severe clinical course
15, 16). Current practice guidelines recommend 
that most patients with active disease should initially be treated 
with corticosteroids
17, 18).
 Although this approach is usually effective 
for symptom control, many patients become either resistant to or 
dependent on these drugs
19). Long-term exposure to corticosteroids 
is also associated with complications such as Cushing’s syndrome, 
and therefore, with increased risk of mortality
17, 18, 20-22). For this 
reason, most clinicians initiate treatment with corticosteroid-sparing 
drugs such as azathioprine, mercaptopurine, or methotrexate once 
corticosteroid resistance or dependence develops.
Infliximab is an anti-tumor necrosis factor (TNF-α ) monoclonal 
antibody that was initially used in corticosteroid-dependent and 
corticosteroid-refractory CD
23). TNF-α  is a pro-inflammatory 
cytokine that plays a key role in the pathophysiology of a number 
of inflammatory disorders, including CD. The use of infliximab 
has been well documented as an effective treatment for moderate 
to severe CD in children in several studies
24, 25). Infliximab, as a 
scheduled treatment, is effective for the induction and maintenance 
of remission in patients with CD
26, 27) (Fig. 1).
Top-down strategy
Early use of infliximab with immunosuppressants, known as top-
down therapy, in patients with newly diagnosed CD has resulted 
in better outcomes in adult patients
28). An 8-week maintenance 
treatment schedule with infliximab has been shown to be a 
cost-effective approach in adult patients with active luminal or 
fistulizing CD
29). Such therapy offers the potential for altering the 
natural history of CD, and is changing treatment paradigms. One 
possible explanation for the prolonged remission with infliximab 
treatment is that this medication might help heal mucosal lesions 
in patients with severe disease as well as those with mild disease
30). 
However, the relatively new concept of an early aggressive or top-
down treatment approach is not yet widely accepted, especially in 
pediatric patients, even although some studies have reported that 
infliximab is more effective in children than in adults
31, 32) (Fig. 1).
The safety of infliximab
The safety profile of infliximab is an important issue, as its 
use and indications are rapidly increasing. Infliximab treatment 
appears to be well tolerated
7), however, anaphylactic reactions and 
symptoms caused by immunosuppression, such as upper respiratory 
tract infections, herpes zoster activation, severe acute bacterial 
infections, and an increased risk of tuberculosis, have all been 
described following treatment with infliximab
8, 9, 33). Pretreatment 
before infliximab infusion may be helpful in ameliorating these side 
effects. Little is known about the potential for long-term toxicity 
in infliximab therapy. After repeated dosing is performed, some 
patients have human antibodies to chimeric TNF-α  antibodies
34). 
Repeated administration of chimeric antibodies may be associated 
with the formation of autoimmune antibodies and a self-limited 
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lupus-like syndrome
35).The development of lymphoma has been 
reported as a possible, although rare, long-term complication of 
anti-TNF therapy in patients with rheumatoid arthritis and CD
36-
38). Several reports of a possible association between concomitant 
infliximab and immunomodulator therapy and hepatosplenic 
T-cell lymphoma (HSTCL) have emerged
37, 38). However, the 
mechanism of this possible association remains unclear. Until 
further evidence emerges, long-term surveillance of patients who 
have used infliximab in combination with immunomodulators is 
warranted.
The experience in Samsung Medical Center 
We have used infliximab as an induction therapy since 2005. 
Our patients had a better response to infliximab treatment  than 
compared to conventional therapy. At 8 weeks, remission was 
achieved in 3 of 11 patients (27.3%) in the step-up group, and in 16 
of 18 patients (88.9%) in the top-down group. At 1 year of follow-
up, remission was maintained in 5 of 11 patients (45.5%) and in 
15 of 18 patients (83.3%) in the step-up and top-down groups, 
respectively
39). At the 1 year follow-up, the relapse rate (23.1%, 3 of 
13 patients) in the top-down group was lower than that (61.5%, 8 
of 13 patients) in the step-up group (P=0.047). At 2 years follow-
up, the relapse rate (38.5%, 5 of 13 patients) in the top-down group 
was lower than that (76.9%, 10 of 13 patients) in the step-up group 
(P=0.047)
40). The mechanism(s) by which the top-down strategy 
yields superior results when compared to step-up treatment with   
regard to remission rates remains unclear. However, it is suggested 
that the patients in the step-up group had a much longer duration 
of disease and that they were exposed to more extensive tissue 
damage. Limbergen et al.
15) reported that infliximab treatment early 
in the disease course may avoid the irreversible tissue damage often 
found in later stages of CD. The potential of infliximab to not only 
induce but also maintain remission is now well studied in adult and 
pediatric CD cohorts
5, 6, 24). 
Conclusion
The incidence and prevalence of CD in Korea is lower than in 
developed countries; however, it is rapidly increasing. There is no 
known cure for CD. Therefore, the goal of treatment is to mitigate 
inflammation and the associated clinical symptoms. The current 
treatment guidelines are designed to maintain remission after 
induction therapy.
According to our experience, early and intensive treatment of 
pediatric CD patients with infliximab, at initial diagnosis, was 
more effective for maintaining remission and reducing flares.
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